Effective decellularization of human skin tissue for regenerative medicine by supercritical carbon dioxide technique. (8th November 2022)

• Record Type: Journal Article
• Authors: Giang, Nguyen Ngan; Trinh, Xuan‐Tung; Han, Jeonghun; Chien, Pham Ngoc; Lee, Jua; Noh, Seong‐Rae; Shin, Yongwoo; Nam, Sun‐Young; Heo, Chan‐Yeong
• Is Part Of: Journal of tissue engineering and regenerative medicine. Volume 16:Number 12(2022)
• Page Start: 1196
• Page End: 1207
• Publication Date: 2022-11-08
• Subjects: ADM -- breast reconstruction -- decellularization -- skin -- supercritical carbon dioxide; Tissue engineering -- Periodicals; Regeneration (Biology) -- Periodicals; 610.28
• DOI: 10.1002/term.3359
• Languages: English
• ISSNs: 1932-6254

Abstract

Abstract: Allotransplantation, performed using an acellular dermal matrix (ADM), plays a significant role in the cultivation of constituted and damaged organs in clinical. Herein, we fabricated an innovative ADM for allografting derived from decellularized human skin by utilizing the supercritical fluid of carbon dioxide to eliminate immunogenic components. By using histological staining, the ADM product demonstrated the successful removal of cellular constituents without exerting any harmful influence on the extracellular matrix. The results from DNA electrophoresis also supported this phenomenon by showing the complete DNA removal in the product, accompanied by the absence of Major Histocompatibility Complex 1, which suggested the supercritical fluid is an effective method for cellular withdrawal. Moreover, the mechanical property of the ADM products, which showed similarity to that of native skin, displayed great compatibility for using our human‐derived ADM as an allograft in clinical treatment. Specifically, the cell viability demonstrated the remarkable biocompatibility of the product to human bio‐cellular environment which was noticeably higher than that of other products. Additionally, the significant increase in the level of growth factors such as vascular endothelial growth factor, urokinase‐type plasminogen activator receptor, granulocyte‐macrophage colony‐stimulating factor suggested the ability to stimulate cellular processes, proving the products to be innovative in the field of regeneration when applied to clinical in the future. This study provides a thoroughly extensive analysis of the new ADM products, enabling them to be applied in industrial and clinical treatment.